ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D
ScripKymera Therapeutics delivered a big win with first-in-human data for an oral STAT6 degrader, a potential new class of medicine for allergic diseases. STAT6 is a key signaling node on the IL-4/IL-13 pa
ScripGilead Sciences' acquisition of Leo Pharma’s signal transducer and activator of transcription 6 (STAT6) program is not just a major boost for the Danish group’s finances but also a nod to the growing
ScripThe pace of new biopharmaceutical financings has slowed as summer enters the last sleepy weeks of August, but the handful of recent significant funding announcements have been quite large, including